AEYE wins FDA clearance for portable AI

AEYE Health said it won U.S. Food and Drug Administration clearance for a portable version of its autonomous diabetic-retinopathy screening system, extending AI eye screening beyond fixed tabletop cameras and into handheld use. The company announced the clearance on April 30, 2024, while Modern Retina and other ophthalmology outlets highlighted the development again on May 21, 2026. The cleared setup pairs AEYE Health’s AEYE-DS software with Optomed’s Aurora handheld retinal camera. AEYE says the system can diagnose more-than-mild diabetic retinopathy from a single non-dilated image of each eye without physician interpretation. ### What exactly did the FDA clear? The April 30, 2024 company release said the FDA cleared “the first ever” fully autonomous AI that diagnoses referable diabetic retinopathy from retinal images captured by a handheld camera. The product combines AEYE-DS, the company’s diagnostic software, with the Aurora portable camera made by Optomed. (prnewswire.com) AEYE Health’s website says AEYE-DS is indicated for healthcare providers to detect more-than-mild diabetic retinopathy in adults with diabetes using one non-mydriatic image per eye. The company also says the software is FDA-cleared for use with both portable and tabletop fundus cameras. ### How is this different from earlier diabetic-eye AI tools? Modern Retina’s archive shows AEYE-DS had already been cleared for use with Topcon’s TRC-NW400 tabletop camera before the handheld authorization. (prnewswire.com) A later company update also said AEYE was seeking additional clearance tied to Topcon’s NW500, underscoring that the portable decision added a new hardware format rather than creating the company’s first FDA-cleared product overall. (aeyehealth.com) Modern Retina also identified the May 2024 decision as the first FDA clearance for a fully autonomous AI for portable diabetic-retinopathy screening. Other ophthalmology trade publications described the same point: the handheld configuration allowed autonomous screening outside the usual fixed imaging setup. ### What are the numbers behind the claim? AEYE Health said the portable clearance was supported by two prospective phase 3 studies. (modernretina.com) In those studies, the company said diagnostic sensitivity was 92% to 93% and specificity was 89% to 94%. The same studies produced the figure that appears most often in coverage: more than 99% of patients received a diagnostic result. (modernretina.com) AEYE and follow-on reports said the system reached that imageability level while using only one image from each eye and rarely requiring dilation. ### Why does the handheld format matter in practice? (eyewire.news) Optomed and AEYE said the cleared product is aimed at point-of-care screening in places such as primary care clinics and other settings where a full ophthalmic imaging suite may not be available. AEYE’s site says the exam takes about one minute, can be ordered from the electronic health record, and can be performed by a nurse or medical assistant while the patient is already in clinic. (eyewire.news) A 2024 Modern Retina report on AEYE’s UMass Memorial Health deployment said screening adherence rose from 29% to 49% within four months after AEYE-DS was integrated into the health system’s electronic medical record. That report referred to the desktop rollout first and said UMass also planned to integrate the newly FDA-cleared handheld option. (mediamice.com) ### What happens next? AEYE Health’s current product materials say AEYE-DS is commercially available and integrates with major electronic health record systems including Epic. The company also says providers can bill screenings under CPT code 92229 when the autonomous exam is performed. As of May 21, 2026, the next concrete milestone is wider deployment of the already-cleared portable system with provider groups and health systems using the Aurora handheld camera and AEYE-DS software. (modernretina.com) Modern Retina’s archive and AEYE’s product page remain the clearest public sources for the cleared indication, hardware pairing, and workflow details. (aeyehealth.com)